Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 18384941)

  • 1. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
    Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
    Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
    Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
    Lexander H; Palmberg C; Hellman U; Auer G; Hellström M; Franzén B; Jörnvall H; Egevad L
    Proteomics; 2006 Aug; 6(15):4370-80. PubMed ID: 16888723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
    Qingyi Z; Lin Y; Junhong W; Jian S; Weizhou H; Long M; Zeyu S; Xiaojian G
    Cancer Invest; 2009 Aug; 27(7):794-801. PubMed ID: 19637042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
    Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E
    Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia.
    Xu K; Ling MT; Wang X; Wong YC
    Prostate Cancer Prostatic Dis; 2006; 9(3):293-7. PubMed ID: 16683014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
    Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
    Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
    Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
    J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
    Chung JC; Oh MJ; Choi SH; Bae CD
    ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
    Lin JF; Xu J; Tian HY; Gao X; Chen QX; Gu Q; Xu GJ; Song JD; Zhao FK
    Int J Cancer; 2007 Dec; 121(12):2596-605. PubMed ID: 17722004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.